Endurant Capital Management LP Affimed N.V. Transaction History

Endurant Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.27 - $4.86 $804,696 - $1.72 Million	-354,492 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.69 - $5.65 $1.31 Million - $2 Million	354,492 New	354,492 $1.55 Million
Q2 2021 Aug 16, 2021	SELL	$7.78 - $11.4 $2.57 Million - $3.77 Million	-330,665 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $1.69 Million - $2.8 Million	330,665 New	330,665 $2.62 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $178M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.